Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • Eating Well (or at Least Not terribly) at Fast Food Resturants
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
DHTV
Popular
Top Rated

Related Research Videos on Diabetes Health TV

New Small Molecule Drugs for Type 2 - Human Trials Underway

Christoph Westphal, MD, Ph.D

New Small Molecule Drugs for Type 2 - Human Trials Underway

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Christoph Westphal, MD, Ph.D - CEO SIRTRIS (GSK)

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

View all Videos…
US Food and Drug Administration Archives
Browse the US Food and Drug Administration Archives
Subscribe to the Research RSS Feed

US Food and Drug Administration

Research RSS Feed RSS
Updated 60 weeks ago
 
Neuropathy Device Maker Files
news
Neuropathy Device Maker Files

NeuroMetrix, Inc., a Massachusetts-based medical device company, has filed a 510(k) form with the US Food and Drug Administration for the SENSUSTM, a pain therapy device for people who suffer diabetic neuropathy. A 510(k) is a "premarket notification" of a company's intent to market a medical product. The FDA then tests the product and provides feedback to the manufacturer. Once the FDA clears the product, its maker can introduce it to the US market.

Comments 1 comment - Apr 24, 2012 - * * * * *

New Type 2 Drug Targets Blood Sugar and Cholesterol
blog
New Type 2 Drug Targets Blood Sugar and Cholesterol

Drug company Merck aims to give people with type 2 diabetes two treatments for the price of one. The new therapy, called Juvisync, was just approved by the US Food and Drug Administration. It's not a radical new treatment, but instead a helpful combination of two familiar standbys: Juvisync unites the active ingredients in blood sugar-lowering Januvia and cholesterol-lowering Zocor in a single tablet.

Comments 0 comments - Dec 10, 2011 - * * * * *

 
©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.